 Analysts at Citi have revised their net present value NPV-based price target for Hikma Pharmaceuticals PLC LSE:HIK, OTC:HKMPF to 19.20 with a 28-11 bull-bear valuation range for the stock. In a note to clients, the analysts said: Our Deconstructed-Buy-Thesis back in August argued the risk-reward was highly attractive, despite carrying deliberately conservative US Generics forecasts 